Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 11/16/21
End: 10/15/25
Due: 10/15/26
Phase: N/A
Priority: Normal
Start: 04/02/25
End: 12/31/28
Due: 12/31/29
Phase: N/A
Priority: Normal
Start: 09/30/22
End: 12/31/24
Due: 12/31/25
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Zanubrutinib in Combination With R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma | NCT04850495 | Yazeed Sawalha | user2@example.com | None | 2021-11-16 | 2025-10-15 | 2026-10-15 | - | - | 2025-07-14 |
| Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma | NCT06536049 | Yazeed Sawalha | user2@example.com | None | 2025-04-02 | 2028-12-31 | 2029-12-31 | - | - | 2025-07-14 |
| Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma | NCT04635683 | Yazeed Sawalha | user2@example.com | None | 2022-09-30 | 2024-12-31 | 2025-12-31 | - | - | 2025-07-14 |